The REX-Osprey Exchange Traded Fund (ETF) launched with a bang, surpassing analysts expectations on its debut trading dayThe REX-Osprey Exchange Traded Fund (ETF) launched with a bang, surpassing analysts expectations on its debut trading day

First US Spot XRP & DOGE ETFs Break the Market With Record Inflows

The REX-Osprey Exchange Traded Fund (ETF) launched with a bang, surpassing analysts’ expectations on its debut trading day.

The REX-Osprey ETF (XRPR), a collaboration between REX Shares and Osprey Funds, went live on the Cboe BZX Exchange on September 18.

Explosive First Day Volumes

XRPR was a fast gainer from the word go, with the product raking in $24 million in volume within its first hour and a half on the market. Bloomberg ETF analyst Eric Balchunas noted that the figure is way more than he had expected. He explained that it was up to five times higher than the first-day totals of any XRP futures ETF.

The same can be said about its counterpart, the Dogecoin-tracking REX-Osprey DOGE ETF (DOJE), which debuted on the same day. On Thursday, Balchunas initially projected that it would likely reach about $2.5 million in daily volume, calling that a decent but unremarkable figure.

However, within the first hour of it going live, trading activity surged to nearly $6 million. “That’s shockingly solid,” he commented, adding that most ETFs see less than $1 million on their opening day.

Greg King, CEO of the company, said in a statement that investors view ETFs as tools for trading and access, noting that the “digital asset revolution is already underway.” He added that they are proud to offer exposure to popular digital assets within the protections of the U.S. ’40 Act ETF framework, a goal it has worked diligently to achieve.

Unique Spot Crypto ETFs

REX Shares and Osprey Funds operate independently but work together strategically to launch spot crypto ETFs. Their latest filings stand out because they were submitted under the Investment Company Act of 1940, a federal law that governs pooled investment funds and is designed to protect investors from conflicts of interest and fraud. This approach is different from the legal framework used by most existing crypto-linked ETFs.

The XRPR fund is set up similarly to the REX-Osprey Solana Staking ETF launched in June, using specific legal methods to operate under U.S. regulations. The Solana fund was the first in the country to track SOL prices and also offer staking rewards.

In another related development, the U.S. The Securities and Exchange Commission (SEC) also gave a go-ahead to the first multi-asset crypto ETF that gives investors exposure to the CoinDesk Large Cap Select Index. Grayscale’s Digital Large-Cap Fund (GDLC) was officially approved for listing and trading on September 18, following a previous stay order by the agency that had delayed its debut.

Elsewhere, the financial watchdog made the ETF listing process easier for issuers by adopting generic registration standards that remove the long 19 (B) filing process.

The post First US Spot XRP & DOGE ETFs Break the Market With Record Inflows  appeared first on CryptoPotato.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.9102
$1.9102$1.9102
-0.21%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26